SCHEMBL2145337

SCHEMBL2145337

CC(C)([SbH2])c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.52
ACHE P22303 1/20 0.52
HSD11B1 P28845 1/20 0.47
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA5A P35218 2/20 0.47
CA9 Q16790 2/20 0.47
ALDH1A1 P00352 6/20 0.47
RECQL P46063 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MAPK1 P28482 1/20 0.45
POLB P06746 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
LMNA P02545 1/20 0.44
CES1 P23141 1/20 0.43
HPGD P15428 1/20 0.42
MAPT P10636 1/20 0.42
CA12 O43570 1/20 0.42
CA3 P07451 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6671840 0.82 HSD17B10 (0.56) HSD17B10ACHEHSD11B1CA1CA2
SCHEMBL677959 0.82 HSD17B10 (0.56) HSD17B10ACHEHSD11B1CA1CA2
SCHEMBL1538287 0.82 HSD17B10 (0.56) HSD17B10ACHEHSD11B1CA1CA2
SCHEMBL397351 0.82 HSD17B10 (0.56) HSD17B10ACHEHSD11B1CA1CA2
SCHEMBL28551166 0.80 HSD17B10 (0.54) HSD17B10ACHEHSD11B1CA1CA2
SCHEMBL677900 0.78 HSD17B10 (0.52) HSD17B10ACHEHSD11B1CA1CA2
SCHEMBL12208260 0.78 HSD11B1 (0.56) HSD17B10ACHEHSD11B1CA1CA2
SCHEMBL2320664 0.78 CA1 (0.56) HSD17B10ACHEHSD11B1CA1CA2
SCHEMBL3154297 0.78 ALDH1A1 (0.52) HSD17B10ACHEHSD11B1CA1CA2
SCHEMBL11453501 0.78 HSD17B10 (0.52) HSD17B10ACHEHSD11B1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008414-B2 Organic antimony compound, process for producing the same, living radical polymerization initiator, process for producing polymer using the same, and polymer OTSUKA CHEMICAL CO., LTD. (JP) 2011-08-30 US disclosed
EP-1767539-B1 ORGANIC ANTIMONY COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER USING THE SAME, AND POLYMER OTSUKA CHEMICAL CO LTD (JP) 2011-07-27 EP disclosed
US-20090299008-A1 Organic antimony compound, process for producing the same, living radical polymerization initiator, process for producing polymer using the same, and polymer OTSUKA CHEMICAL CO., LTD. (JP) 2009-12-03 US disclosed
EP-1767539-A1 ORGANIC ANTIMONY COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER USING THE SAME, AND POLYMER OTSUKA CHEMICAL COMPANY, LTD. (JP) 2007-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090299008-A1 Organic antimony compound, process for producing the same, living radical polymerization initiator, process for producing polymer using the same, and polymer AOC2, ODC1, MCM7 HSD17B10 2192/4885ACHE 352/4885HSD11B1 3868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.